Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6472
-0.0291-4.30%
Post-market: 0.65480.0076+1.17%19:50 EDT
Volume:11.50M
Turnover:7.65M
Market Cap:157.27M
PE:-0.87
High:0.7060
Open:0.6759
Low:0.6400
Close:0.6763
52wk High:3.39
52wk Low:0.1611
Shares:243.00M
Float Shares:214.26M
Volume Ratio:0.22
T/O Rate:5.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-184.82%
PB:-5.42
PE(LYR):-0.36

Loading ...

Outlook Therapeutics Inc - Lender Confirms Existing Note Is Not in Default

THOMSON REUTERS
·
Mar 16

Outlook Therapeutics Inc - Proceeds From New Note to Pay Down Existing Note, $10.8 Mln Principal and Interest Remaining on Existing Note

THOMSON REUTERS
·
Mar 16

Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Dow Jones
·
Mar 16

Outlook Therapeutics director Julia A. Haller to step down effective March 10, 2026

Reuters
·
Mar 12

Outlook Therapeutics provides update following FDA meeting on ONS-5010

TIPRANKS
·
Mar 06

Outlook Therapeutics Updates on FDA Type A Meeting for ONS-5010/LYTENAVA BLA

Reuters
·
Mar 06

Outlook Therapeutics Inc - Evaluating Regulatory Options for Ons-5010/Lytenava U.S. Approval

THOMSON REUTERS
·
Mar 06

Outlook Therapeutics: to Continue Engaging in Discussions With FDA to Clarify Agency's Views on Confirmatory Evidence & Appropriate Path Forward

THOMSON REUTERS
·
Mar 06

Outlook Therapeutics Provides Update Following Type a Meeting With FDA Regarding Ons-5010/Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Mar 06

Outlook enters distribution agreement for sale of Lytenava in Switzerland

TIPRANKS
·
Feb 19

Outlook Therapeutics Signs Exclusive LYTENAVA Distribution Agreement With Mediconsult AG in Switzerland

Reuters
·
Feb 19

Outlook Therapeutics: Partnership Advances European Commercial Expansion Strategy, With Lytenava Expected to Launch in Switzerland in 2027

THOMSON REUTERS
·
Feb 19

Outlook Therapeutics Inc - Mediconsult to Market and Distribute Lytenava in Switzerland

THOMSON REUTERS
·
Feb 19

Outlook Therapeutics Expands European Footprint With Exclusive Commercial Distribution Agreement With Mediconsult Ag for Lytenava™ (Bevacizumab Gamma) in Switzerland

THOMSON REUTERS
·
Feb 19

Nasdaq Warns Outlook Therapeutics of Delisting Risk After Sub-$1 Share Price Streak

Reuters
·
Feb 19